Oral semaglutide dosing: what the tablet schedule actually involves

The misconception worth clearing up: the tablet doses are not the same as the injection doses

One of the most common points of confusion around oral semaglutide dosing is the assumption that the tablet milligrams map neatly onto the injection milligrams. They do not. The Wegovy injection tops out at 2.4 mg weekly (or 7.2 mg on the newer higher-dose pen). The Wegovy tablet maintenance dose is 25 mg daily. Seeing that number for the first time, people sometimes wonder whether it represents a different medicine or an error. It is neither. Semaglutide is absorbed very differently when swallowed rather than injected, so the tablet contains semaglutide co-formulated with an absorption enhancer called SNAC; the much higher milligram figure reflects what is needed for an equivalent amount of the active ingredient to reach the bloodstream after passing through the gut wall.

There is a related confusion that is worth letting go gently: some people arrive having heard that the oral semaglutide tablets follow the same schedule as Rybelsus, which also contains oral semaglutide but is licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg. Those are a separate product with a separate dose ladder. The Wegovy tablet steps (1.5 mg, 4 mg, 9 mg, 25 mg) are the weight-loss tablet steps. The Rybelsus steps should never be treated as rungs on the Wegovy ladder.

Getting this clear matters because prescribers assess suitability against the licensed schedule, and a patient who expects the injection pattern may be surprised by the titration that the tablet actually requires. Understanding it in advance makes the process easier.

What happens at each dose level and why the pace is set the way it is

The escalation through 1.5 mg, 4 mg, 9 mg and 25 mg is paced at a minimum of one month per level. That timing is not arbitrary. Gastrointestinal side effects (nausea, loose stools, stomach discomfort) are the most commonly reported responses to semaglutide, and a gradual increase gives the gut time to adjust before the dose rises again. In the OASIS 4 phase-3 trial that supported the MHRA's approval, gastrointestinal events were reported in about 74% of participants on oral semaglutide versus around 42% on placebo; the majority were mild to moderate and tended to ease over time. Rushing the escalation does not make the medicine work faster, it mainly increases the chance of unpleasant side effects that make continuing difficult.

The trial ran for 64 weeks and found an average weight loss of around 13.6% across all participants, rising to approximately 17% among those who adhered fully to treatment. That second figure, which you may see cited elsewhere, only applies to full adherence; it is not the general average. The Wegovy pill overview covers the full trial context if you want to read further. Practically speaking, the dose a prescriber targets depends on how a patient tolerates each level, not on a fixed timetable imposed from the outside.

For people switching from the 2.4 mg weekly injection, the licensed approach allows moving directly to the 25 mg tablet, bypassing the lower rungs, subject to clinical assessment. That is a prescriber-led decision rather than something to self-manage.

How to take each dose correctly, because the method is part of the dosing

The absorption mechanism for the Wegovy tablet is sensitive to what is in the stomach at the time of dosing. For SNAC to carry semaglutide across the gut lining effectively, the stomach needs to be empty and the environment needs to be relatively alkaline. That is why the instructions specify first thing in the morning, with a small amount of plain water (up to around 120 ml) and a gap of at least 30 minutes before food, other drinks (including coffee or tea), or any other oral medicines.

These conditions are non-negotiable in a way that is different from many once-daily tablets people are used to. Taking the tablet with a full glass of water, or with a morning coffee, or shortly before breakfast, is likely to reduce absorption substantially. The MHRA's approval communications and the medicine's Patient Information Leaflet set out the full administration requirements; a prescriber will go through these at the point of approval. The tablet is swallowed whole, not chewed, split or dissolved.

Storage is meaningfully simpler than the injection: no refrigerator required. The tablet is kept at room temperature, making it easier to manage at home and when travelling. If you are also exploring alternatives to tablet formats, our semaglutide oral drops page explains how that option works. For a fuller look at how the tablet compares with the injection in practical terms, the semaglutide oral form comparison page covers that ground.

Who can be prescribed oral semaglutide and what the clinical review covers

The Wegovy tablet was approved by the MHRA on 11 June 2026 for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. It is not available on the NHS at the time of writing (a NICE appraisal would be required before NHS commissioning could begin) so access is currently via private prescription only.

A prescriber assessing suitability for the tablet considers the full clinical picture: BMI, medical history, current medicines, and whether starting the escalation schedule is appropriate for this person right now. Certain histories (including pancreatitis, some thyroid conditions, and significant gastrointestinal disease) require careful prescriber review. Oral semaglutide is not recommended during pregnancy, while breastfeeding, or for people actively trying to conceive, and it is not licensed for under-18s.

The cost context for the Wegovy tablet is worth reading alongside this if you are weighing up private treatment options. At nume, every consultation is reviewed by a GPhC-registered prescriber (a real clinician reads your answers, not an automated system) and that review happens the same day. If you are curious whether the tablet or the injection might suit your situation better, our prescribers can discuss that as part of the assessment. You can start your free consultation whenever you are ready.